Advertisement
Singapore markets closed
  • Straits Times Index

    3,313.48
    +8.49 (+0.26%)
     
  • Nikkei

    38,787.38
    -132.88 (-0.34%)
     
  • Hang Seng

    19,553.61
    +177.08 (+0.91%)
     
  • FTSE 100

    8,420.26
    -18.39 (-0.22%)
     
  • Bitcoin USD

    67,225.88
    +960.53 (+1.45%)
     
  • CMC Crypto 200

    1,373.16
    -0.68 (-0.05%)
     
  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     
  • Dow

    40,003.59
    +134.21 (+0.34%)
     
  • Nasdaq

    16,685.97
    -12.35 (-0.07%)
     
  • Gold

    2,419.80
    +34.30 (+1.44%)
     
  • Crude Oil

    80.00
    +0.77 (+0.97%)
     
  • 10-Yr Bond

    4.4200
    +0.0430 (+0.98%)
     
  • FTSE Bursa Malaysia

    1,616.62
    +5.51 (+0.34%)
     
  • Jakarta Composite Index

    7,317.24
    +70.54 (+0.97%)
     
  • PSE Index

    6,618.69
    -9.51 (-0.14%)
     

J&J unit to start mid-stage COVID-19 vaccine trials in Spain

FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the NYSE in New York

BARCELONA (Reuters) - Johnson & Johnson's <JNJ.N> Janssen unit will begin mid-stage trials of its COVID-19 vaccine in Spain on Monday, the programme's lead investigator said.

Alberto Borobia said 190 people would take part in the country's trials, which will take place in three hospitals and be concluded by Sept. 22.

The Spanish study is part of mid-stage, or Phase II, trials of the vaccine that are being carried out in three countries, also including the Netherlands and Germany. The trials in the three countries will last two months and include 550 participants in total.

(Reporting by Graham Keeley; Editing by Pravin Char)